Through the partnership, HHS’ Biomedical Advanced Research and Development Authority will give Summit $32 million over two years to conduct two Phase 3 clinical trials of its experimental drug Ridinilazole.
The drugmaker is also eligible to receive a three-year extension on the contract with total potential funding of $62 million.
To learn more about C diff, click here.
More articles on infection control:
Study suggests possible link between repeat flu vaccination and miscarriage
Study: Antibiotic use may boost superbug spread in nursing homes
Pet store puppies sicken 39 people in multistate bacterial outbreak
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
